587 related articles for article (PubMed ID: 26387848)
1. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology.
Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P
ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848
[TBL] [Abstract][Full Text] [Related]
2. Preparation, characterization, and in vitro tumor-suppressive effect of anti-miR-21-equipped RNA nanoparticles.
Zhang T; Wu Y; Yang D; Wu C; Li H
Biochem Biophys Res Commun; 2021 Jun; 558():107-113. PubMed ID: 33906109
[TBL] [Abstract][Full Text] [Related]
3. Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133.
Yin H; Xiong G; Guo S; Xu C; Xu R; Guo P; Shu D
Mol Ther; 2019 Jul; 27(7):1252-1261. PubMed ID: 31085078
[TBL] [Abstract][Full Text] [Related]
4. Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.
Binzel DW; Shu Y; Li H; Sun M; Zhang Q; Shu D; Guo B; Guo P
Mol Ther; 2016 Aug; 24(7):1267-77. PubMed ID: 27125502
[TBL] [Abstract][Full Text] [Related]
5. Anti-EGF Receptor Aptamer-Guided Co-Delivery of Anti-Cancer siRNAs and Quantum Dots for Theranostics of Triple-Negative Breast Cancer.
Kim MW; Jeong HY; Kang SJ; Jeong IH; Choi MJ; You YM; Im CS; Song IH; Lee TS; Lee JS; Lee A; Park YS
Theranostics; 2019; 9(3):837-852. PubMed ID: 30809312
[TBL] [Abstract][Full Text] [Related]
6. Triple negative breast cancer therapy with CDK1 siRNA delivered by cationic lipid assisted PEG-PLA nanoparticles.
Liu Y; Zhu YH; Mao CQ; Dou S; Shen S; Tan ZB; Wang J
J Control Release; 2014 Oct; 192():114-21. PubMed ID: 25016158
[TBL] [Abstract][Full Text] [Related]
7. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase.
Bayraktar R; Pichler M; Kanlikilicer P; Ivan C; Bayraktar E; Kahraman N; Aslan B; Oguztuzun S; Ulasli M; Arslan A; Calin G; Lopez-Berestein G; Ozpolat B
Oncotarget; 2017 Feb; 8(7):11641-11658. PubMed ID: 28036267
[TBL] [Abstract][Full Text] [Related]
9. Favorable biodistribution, specific targeting and conditional endosomal escape of RNA nanoparticles in cancer therapy.
Xu C; Haque F; Jasinski DL; Binzel DW; Shu D; Guo P
Cancer Lett; 2018 Feb; 414():57-70. PubMed ID: 28987384
[TBL] [Abstract][Full Text] [Related]
10. RNA nanoparticles harboring annexin A2 aptamer can target ovarian cancer for tumor-specific doxorubicin delivery.
Pi F; Zhang H; Li H; Thiviyanathan V; Gorenstein DG; Sood AK; Guo P
Nanomedicine; 2017 Apr; 13(3):1183-1193. PubMed ID: 27890659
[TBL] [Abstract][Full Text] [Related]
11. Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer.
Zhang L; Mu C; Zhang T; Wang Y; Wang Y; Fan L; Liu C; Chen H; Shen J; Wei K; Li H
ACS Appl Mater Interfaces; 2020 Jul; 12(29):32360-32371. PubMed ID: 32613835
[TBL] [Abstract][Full Text] [Related]
12. Nanoparticle orientation to control RNA loading and ligand display on extracellular vesicles for cancer regression.
Pi F; Binzel DW; Lee TJ; Li Z; Sun M; Rychahou P; Li H; Haque F; Wang S; Croce CM; Guo B; Evers BM; Guo P
Nat Nanotechnol; 2018 Jan; 13(1):82-89. PubMed ID: 29230043
[TBL] [Abstract][Full Text] [Related]
13. Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA.
Zhang L; Mu C; Zhang T; Yang D; Wang C; Chen Q; Tang L; Fan L; Liu C; Shen J; Li H
J Nanobiotechnology; 2021 Jan; 19(1):13. PubMed ID: 33413427
[TBL] [Abstract][Full Text] [Related]
14. RNA Micelles for the Systemic Delivery of Anti-miRNA for Cancer Targeting and Inhibition without Ligand.
Yin H; Wang H; Li Z; Shu D; Guo P
ACS Nano; 2019 Jan; 13(1):706-717. PubMed ID: 30543397
[TBL] [Abstract][Full Text] [Related]
15.
Wan X; Sun R; Bao Y; Zhang C; Wu Y; Gong Y
Mol Pharm; 2021 Nov; 18(11):3990-3998. PubMed ID: 34591491
[TBL] [Abstract][Full Text] [Related]
16. Tumor targeting and therapeutic assessments of RNA nanoparticles carrying α9-nAChR aptamer and anti-miR-21 in triple-negative breast cancers.
Liao YC; Cheng TC; Tu SH; Chang J; Guo P; Chen LC; Ho YS
Mol Ther Nucleic Acids; 2023 Sep; 33():351-366. PubMed ID: 37547295
[TBL] [Abstract][Full Text] [Related]
17. Systemic Delivery of Tumor-Targeting siRNA Nanoparticles against an Oncogenic LncRNA Facilitates Effective Triple-Negative Breast Cancer Therapy.
Vaidya AM; Sun Z; Ayat N; Schilb A; Liu X; Jiang H; Sun D; Scheidt J; Qian V; He S; Gilmore H; Schiemann WP; Lu ZR
Bioconjug Chem; 2019 Mar; 30(3):907-919. PubMed ID: 30739442
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Bone Marrow-Derived Mesenchymal Stem Cells Homing Towards Triple-Negative Breast Cancer Microenvironment Using an Anti-PDGFRβ Aptamer.
Camorani S; Hill BS; Fontanella R; Greco A; Gramanzini M; Auletta L; Gargiulo S; Albanese S; Lucarelli E; Cerchia L; Zannetti A
Theranostics; 2017; 7(14):3595-3607. PubMed ID: 28912898
[TBL] [Abstract][Full Text] [Related]
19. Using Planar Phi29 pRNA Three-Way Junction to Control Size and Shape of RNA Nanoparticles for Biodistribution Profiling in Mice.
Haque F; Xu C; Jasinski DL; Li H; Guo P
Methods Mol Biol; 2017; 1632():359-380. PubMed ID: 28730451
[TBL] [Abstract][Full Text] [Related]
20. Identification of Specific miRNA Signature in Paired Sera and Tissue Samples of Indian Women with Triple Negative Breast Cancer.
Thakur S; Grover RK; Gupta S; Yadav AK; Das BC
PLoS One; 2016; 11(7):e0158946. PubMed ID: 27404381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
